07:00 , Aug 22, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Aldosterone synthase (ALDOS; CYP11B2); cytochrome P450 17 a-hydroxylase/C17, 20 lyase (CYP17)...
07:00 , May 24, 2010 |  BC Week In Review  |  Company News

ElexoPharm, Merck deal

ElexoPharm and Merck partnered to develop candidates targeting aldosterone synthase ( ALDOS; CYP11B2) to treat cardiovascular disease. Merck is responsible for all development, regulatory filings, manufacturing and commercialization of compounds under the deal....
07:00 , Apr 26, 2010 |  BC Week In Review  |  Clinical News

LCI699: Development discontinued

Novartis disclosed that last quarter it discontinued development of LCI699 due to a "safety issue" related to an impaired stress response. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland   Product: LCI699   Business: Cardiovascular   Molecular target: ...
07:00 , Aug 21, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease ...
07:00 , Jul 14, 2008 |  BioCentury  |  Strategy

Prodigal returns

Novartis AG may not have surprised the market with its bid to acquire Speedel Holding Ltd., but the manner of the approach certainly caught the Swiss biotech’s board off guard. Alice Huxley, president and CEO,...
08:00 , Mar 20, 2006 |  BioCentury  |  Product Development

More than skin deep

NitroMed Inc. has taken the first steps toward understanding why its BiDil heart failure treatment works better in African Americans than in white patients. Ultimately, this could lead to a more scientific - and potentially...